Table 2.
Principal Characteristics of Patients and Disease Presentations
| All Patients (n=155) |
TARE_alone (n=55) |
TARE_sorafenib (n=74) |
TARE_alternative (n=26) |
|
|---|---|---|---|---|
| Median age, years (range) | 65 (15–85) | 70 (29–84) | 63 (27–84) | 64.5 (17–85) |
| Patients aged <65 years, n (%) | 71 (45.8) | 15 (27.3) | 43 (58.1) | 13 (50) |
| Patients aged ≥65 years, n (%) | 84 (54.2) | 40 (72.7) | 31 (41.9) | 13 (50) |
| Sex, n (%) | ||||
| Male | 117 (75.5) | 42 (76.4) | 58 (78.4) | 17 (65.4) |
| Female | 38 (24.5) | 13 (23.6) | 16 (21.6) | 9 (34.6) |
| Ethnicity, n (%) | ||||
| Non-Hispanic white | 109 (70.3) | 46 (83.6) | 46 (62.2) | 17 (65.4) |
| Hispanic | 16 (10.3) | 5 (9.1) | 9 (12.2) | 2 (7.7) |
| Asian | 16 (10.3) | 1 (1.8) | 10 (13.5) | 5 (19.2) |
| Black | 14 (9.0) | 3 (5.5) | 9 (12.2) | 2 (7.7) |
| Etiology, n (%) | ||||
| Hepatitis B | 17 (11.0) | 3 (5.5) | 13 (17.6) | 1 (3.8) |
| Hepatitis C | 52 (33.5) | 22 (40) | 20 (27) | 10 (38.5) |
| Metabolic | 36 (23.2) | 17 (30.9) | 14 (18.9) | 5 (19.2) |
| Alcoholic | 11 (7.1) | 4 (7.3) | 5 (6.8) | 2 (7.7) |
| Combined | 6 (3.9) | 0 | 6 (8.1) | 0 |
| Unknown | 33 (21.3) | 9 (16.4) | 16 (21.6) | 8 (30.8) |
| Tumor differentiation, n (%) | ||||
| Well | 41 (26.5) | 13 (23.6) | 19 (25.7) | 9 (34.6) |
| Moderately | 50 (32.3) | 17 (30.9) | 25 (33.8) | 8 (30.8) |
| Poorly | 17 (11) | 3 (5.5) | 10 (13.5) | 4 (15.4) |
| Unknown | 10 (6.5) | 4 (7.3) | 5 (6.8) | 1 (3.8) |
| Fibrolamellar | 3 (1.9) | 1 (1.8) | 1 (1.4) | 1 (3.8) |
| No biopsy | 34 (21.9) | 17 (30.9) | 14 (18.9) | 3 (11.5) |
| ECOG, n (%) | ||||
| 0 | 75 (48.4) | 27 (49.1) | 38 (51.4) | 10 (38.5) |
| 1 | 74 (47.7) | 25 (45.5) | 34 (45.9) | 15 (57.7) |
| 2 | 5 (3.2) | 2 (3.6) | 2 (2.7) | 1 (3.8) |
| 3 | 1 (0.6) | 1 (1.8) | 0 | 0 |
| BCLC, n (%) | ||||
| A | 5 (3.2) | 5 (9.1) | 0 | 0 |
| B | 39 (25.2) | 22 (40) | 16 (21.6) | 1 (3.8) |
| C | 110 (71.0) | 27 (49.1) | 58 (78.4) | 25 (96.2) |
| D | 1 (0.6) | 1 (1.8) | 0 | 0 |
| Cirrhosis, n (%) | ||||
| Absence | 49 (31.6) | 13 (23.6) | 27 (36.5) | 9 (34.6) |
| Presence | 106 (68.4) | 42 (76.4) | 47 (63.5) | 17 (65.4) |
| Ascites, n (%) | ||||
| Absence | 141 (91) | 49 (89.1) | 69 (93.2) | 23 (88.5) |
| Presence | 14 (9) | 6 (10.9) | 5 (6.8) | 3 (11.5) |
| Vascular invasion, n (%) | ||||
| Absence | 115 (74.2) | 55 (100) | 48 (64.9) | 12 (46.2) |
| Portal vein | 36 (23.2) | 0 | 22 (29.7) | 14 (53.8) |
| Hepatic vein | 3 (1.9) | 0 | 3 (4.1) | 0 |
| Inferior vena cava | 1 (0.6) | 0 | 1 (1.4) | 0 |
| Lymph node metastasis, n (%) | ||||
| Absence | 137 (88.4) | 55 (100) | 63 (85.1) | 19 (73.1) |
| Presence | 18 (11.6) | 0 | 11 (14.9) | 7 (26.9) |
| Distant metastasis, n (%) | ||||
| Absence | 135 (87.1) | 55 (100) | 61 (82.4) | 19 (73.1) |
| Presence | 20 (12.9) | 0 | 13 (17.6) | 7 (26.9) |
| Extrahepatic disease,a n (%) | ||||
| Absence | 125 (80.6) | 55 (100) | 55 (74.3) | 15 (57.7) |
| Presence | 30 (19.4) | 0 | 19 (25.7) | 11 (42.3) |
| Number of tumors, n (%) | ||||
| Single | 26 (16.8) | 10 (18.2) | 9 (12.2) | 7 (26.9) |
| Multiple | 129 (83.2) | 45 (81.8) | 65 (87.8) | 19 (73.1) |
| Lobar involvement, n (%) | ||||
| Unilobar | 62 (40) | 32 (58.2) | 20 (27) | 10 (38.5) |
| Bilobar | 93 (60) | 23 (41.8) | 54 (73) | 16 (61.5) |
| Intrahepatic tumor, n (%) | ||||
| ≤50% | 106 (68.4) | 55 (100) | 34 (45.9) | 17 (65.4) |
| >50% | 49 (31.6) | 0 | 40 (54.1) | 9 (34.6) |
| AFP (ng/mL)b, median (range) | 68.0 (1.5–656,373.0) | 18.2 (1.9–109,307.7) | 102.9 (1.5–656,373.0) | 240.2 (2.2–44,508.4) |
| <400 | 107 (69.5) | 45 (81.8) | 47 (63.5) | 15 (60) |
| ≥400 | 47 (30.5) | 10 (18.2) | 27 (36.5) | 10 (40) |
| Albumin–bilirubin grade, n (%) | ||||
| 1 | 82 (52.9) | 28 (50.9) | 41 (55.4) | 13 (50) |
| 2 | 73 (47.1) | 27 (49.1) | 33 (44.6) | 13 (50) |
| Child–Pugh class, n (%) | ||||
| A | 144 (92.9) | 50 (90.9) | 71 (95.9) | 23 (88.5) |
| B | 11 (7.1) | 5 (9.1) | 3 (4.1) | 3 (11.5) |
Notes: aIncluded lymph node and distant metastasis; bAFP unavailable in one TARE_alternative patient.